AI Article Synopsis
- This review evaluates the effectiveness of local and systemic antimicrobials as additional treatments for periodontitis, focusing on addressing the limitations of standard nonsurgical methods.
- Research included randomized clinical trials from 2008 to 2012 and highlighted that systemic antimicrobials, like amoxicillin and metronidazole, show benefits in both aggressive and chronic periodontitis.
- Despite the demonstrated clinical efficacy of these antimicrobials, there is insufficient evidence for standardized protocols regarding their use, including specific products and dosages.
Article Abstract
Context: This review aimed to update the current evidence on the efficacy of the adjunctive use of local and systemic antimicrobials in the treatment of periodontitis and to assess whether it might improve the clinical limitations and shortcomings of standard nonsurgical treatment in the management of periodontitis.
Evidence Acquisition: Relevant randomized clinical trials (RCT) with more than 3 months of follow-up, published from 2010 to 2012 for systemic antimicrobials and from 2008 to 2012 for local antimicrobials, were searched in Medline and critically analyzed. Scientific evidence evaluated in different systematic reviews and reviews presented at European and World Workshops were also included. Only adjunctive therapies were considered in the present review: articles comparing debridement alone or plus placebo, versus debridement plus systemic or local antimicrobials were included.
Evidence Synthesis: Adjunctive systemic antimicrobials have been evaluated both in aggressive and chronic periodontitis: in aggressive periodontitis, amoxicillin and metronidazole have been extensively studied, reporting clinical and microbiological benefits; in chronic periodontitis, different products are under scrutiny, such as azithromycin. The clinical efficacy of local antimicrobials, although extensively demonstrated, is still surrounded by a constant debate on the cost-effectiveness evaluation and on its adequate indications.
Conclusions: Despite the clinical efficacy of the adjunctive use of local and systemic antimicrobials, demonstrated in RCTs and in systematic reviews, there is a lack of evidence to support well-defined clinical protocols, including products and dosages.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/S1532-3382(12)70013-1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Microsporidiosis in Patients with Autoimmune Diseases Undergoing Monoclonal Antibody Associated Therapy.
Mycopathologia
January 2025
Sorbonne Université, Inserm U1135, Centre d'Immunologie et de Maladies Infectieuses (Cimi-Paris), AP-HP, Hôpital Saint-Antoine, Service de Parasitologie-Mycologie, 184 rue Faubourg Saint Antoine, 175012, Paris, France.
We present Enterocytozoon bieneusi infection in four patients with autoimmune diseases undergoing prolonged monoclonal antibody therapies. Two patients suffered from inflammatory bowel disease and received anti-TNF therapies, whereas two other patients suffered from systemic lupus erythematosus with renal involvement and received anti-CD20 or anti-BLyS protein therapies. Three out of four patients consulted for diarrhea with abdominal pain without intestinal inflammation or bleeding at the time of sampling.
View Article and Find Full Text PDFComparative study of a commercial formula containing natural antimicrobials versus oral cephalexin or topical chlorhexidine-miconazole therapies for treating superficial pyoderma in dogs.
Vet Dermatol
January 2025
Department of Veterinary Medicine, School of Medicine and Life Sciences, Pontifícia Universidade Católica Do Paraná, Curitiba, Brazil.
Background: Chronic and recurrent pyoderma in dogs is driving a growing interest in natural antimicrobial products that offer minimal adverse effects and avoid antibiotic resistance.
Objectives: Evaluate the safety and efficacy of dermatological products with antimicrobial peptides and plant extracts, comparing them to chlorhexidine + miconazole and cephalexin therapy for superficial pyoderma in dogs.
Materials And Methods: Forty-five dogs with superficial pyoderma underwent clinical, cytopathological and microbiological diagnosis, and were randomly assigned to Group 1 (G1) treated with shampoo (two weekly baths) and lotion (twice daily on the affected areas) containing natural antimicrobials; Group 2 (G2) treated with two weekly baths using a therapeutic shampoo containing 2% chlorhexidine and 2.
Weakened Airway Epithelial Junctions and Enhanced Neutrophil Elastase Release Contribute to Age-Dependent Bacteremia Risk Following Pneumococcal Pneumonia.
Aging Cell
January 2025
Department of Molecular Biology and Microbiology, Tufts University School of Medicine, Boston, MA, USA.
Streptococcus pneumoniae (Sp; pneumococcus), the most common agent of community-acquired pneumonia, can spread systemically, particularly in the elderly, highlighting the need for adjunctive therapies. The airway epithelial barrier defends against bacteremia and is dependent upon apical junctional complex (AJC) proteins such as E-cadherin. After mouse lung challenge, pneumolysin (PLY), a key Sp virulence factor, stimulates epithelial secretion of an inflammatory eicosanoid, triggering the infiltration of polymorphonuclear leukocytes (PMNs) that secrete high levels of neutrophil elastase (NE), thus promoting epithelial damage and systemic infection.
View Article and Find Full Text PDFIn vivo systemic vancomycin determination from polymethyl methacrylate and morselized bone allograft used in two stage septic knee revision arthroplasty.
Germs
September 2024
MD, PhD, Professor, Department of Orthopedics, Carol Davila University of Medicine and Pharmacy, No. 8 Eroii Sanitari Boulevard, Bucharest, 050474, Romania.
Introduction: This paper examines the use of local antibiotic therapy in one-stage septic revision surgery for late periprosthetic joint infections (PJIs). This case study suggests that morselized bone allografts impregnated with antibiotics in powder form are a preferable alternative to polymethyl methacrylate (PMMA) because they can generate higher local antibiotic concentrations. Current research also recommends using vancomycin and aminoglycosides as the preferred choice of antibiotics, as they may have low diffusion in tissues when administered intravenously, but are effective when administered locally.
View Article and Find Full Text PDFSuperficial Fungal Infections and Artificial Intelligence: A Review on Current Advances and Opportunities: REVISION.
Mycoses
January 2025
School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Background: Superficial fungal infections are among the most common infections in world, they mainly affect skin, nails and scalp without further invasion. Superficial fungal diseases are conventionally diagnosed with direct microscopy, fungal culture or histopathology, treated with topical or systemic antifungal agents and prevented in immunocompetent patients by improving personal hygiene. However, conventional diagnostic tests can be time-consuming, also treatment can be insufficient or ineffective and prevention can prove to be demanding.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!